Podcasts Answers from the Lab

William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D., interim chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic. In this episode, Dr. Pritt and Dr. Morice discuss their new roles at Mayo Clinic and update listeners on the latest legislative news impacting the laboratory and diagnostic industries. They also highlight the launch of MayoComplete, Mayo Clinic Laboratories’ robust suite of oncology and hematology testing that uses next-generation sequencing to identify and evaluate presence of mutations.

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new assay for gastrointestinal stromal tumors, or GIST. The panel covers multiple mutations, to better inform diagnosis and treatment options.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and CEO and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss how traveling and gathering impacts respiratory virus spread, and how testing and lab stewardship will be critical in the months ahead. They also highlight Dr. Pritt’s parasitology blog, Creepy Dreadful Wonderful Parasites, which just posted its 700th case.

In this test specific episode of the "Answers From the Lab" podcast, Ruifeng (Ray) Guo, M.D., Ph.D., explains how Mayo Clinic Laboratories' comprehensive melanoma panel better informs prognosis and treatment.

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new colorectal cancer panel. The assay covers more genes to better inform decision-making about prognosis, targeted therapies and a hereditary cancer syndrome.

Ying-Chun Lo, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated lung panel can better guide clinical decision-making, particularly about targeted lung cancer therapies.

Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' pediatric autoimmune/CNS testing can better guide the treatment of autoimmune neurological diseases in children. The tailored evaluation covers only biomarkers relevant to pediatric presentations of the diseases.

On this week’s episode of the "Answers From the Lab" podcast, Bobbi Pritt, M.D., is joined by Matthew Binnicker, Ph.D., director of the Clinical Virology Laboratory at Mayo Clinic. Dr. Pritt and Dr. Binnicker discuss why it could be a rough influenza season, testing options for patients with respiratory infections, and how to protect yourself from illness.

Loralie Langman, Ph.D., explains the difference between chain of custody and clinical toxicology testing. Chain of custody is a process used for toxicology testing when the results might have legal implications for the individual tested. Clinical toxicology testing is used for routine medical care. Mayo Clinic Laboratories offers a full range of clinical and forensic toxicology testing.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and CEO and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss the stabilization of monkeypox and COVID-19, the shift from pandemic to endemic status, the increase in global virus outbreaks, and the role that laboratory medicine plays in this changing health environment.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and CEO and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice cover current trends for monkeypox and COVID-19, their thoughts as autumn begins, getting back to infection prevention basics, and a quick legislation update.

William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and CEO and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss the Saving Access to Laboratory Services Act (SALSA), how it is designed to mitigate harmful effects of the Protecting Access to Medicare Act (PAMA), where the legislation stands today, and how to get involved in advocacy.

Katherine Geiersbach, M.D., explains how Mayo Clinic Laboratories' PIK3CA assay informs breast cancer treatment. The assay identifies patients eligible for a certain second-line therapy when initial treatment has failed.